Search the Newsreel

Baker Bros. Advisors (IDYA) reports 5.2% IDEAYA stake and capped warrants

Baker Bros. Advisors and its related entities have disclosed a 5.2% beneficial ownership stake in IDEAYA Biosciences, Inc. (IDYA), totaling 5,010,030 shares based on 96,375,637 shares outstanding as of June 30, 2026. The firm also holds prefunded warrants with a low exercise price but …

Vidya Wires Share Price, Stock Price - NSE/BSE Live

IDEAYA Biosciences (IDYA) Short Interest & Short Float | Updated Aug 2026

IDEAYA Biosciences (IDYA) reported a short interest of 10.11 million shares as of July 31, 2026, marking a 5.64% increase from the previous period. This represents 12.08% of the public float and a short interest ratio of 13.2 days to cover. The article provides …

How (IDYA) Movements Inform Risk Allocation Models

This article from Stock Traders Daily discusses how Ideaya Biosciences Inc. (NASDAQ: IDYA) movements inform risk allocation models. It highlights key findings such as a strong near-term sentiment possibly leading to a long-term positive bias, and an exceptional 49.4:1 risk-reward setup. The analysis provides …

How Investors Are Reacting To IDEAYA Biosciences (IDYA) Q2 Losses And IDE892 Trial Expansion

IDEAYA Biosciences reported Q2 2026 results with $8.86 million in revenue and a widened net loss of $112.45 million, or $1.22 per share. Despite the losses, the company advanced IDE892 into Part 2 monotherapy expansion for MTAP-deleted solid tumors, which is a positive development …

LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58

LifeSci Capital has reiterated its Buy rating for IDEAYA Biosciences (IDYA.US) and maintained its target price at $58. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.

IDEAYA Biosciences (IDYA) Stock Could Be Fully Valued After Trial Progress

IDEAYA Biosciences (IDYA) stock has delivered a 61.0% return over five years, but its current P/S ratio of 14.9x suggests it might be overvalued compared to the biotech industry average and a fair P/S of 4.3x implied by the model. While progress in its …

IDEAYA Biosciences, Inc. (IDYA) stock price, news, quote and history

This article provides a detailed financial overview of IDEAYA Biosciences, Inc. (IDYA), including its current stock price, historical data, and analyst ratings. It highlights the company's focus on developing targeted therapeutics for oncology and lists its key drug candidates and strategic alliances. The report …

The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership

IDEAYA Biosciences recently reported a wider Q2 2026 net loss of US$112.45 million, or US$1.22 per share, and an overall wider six-month loss compared to the previous year. Despite this, the company is advancing its precision oncology pipeline, initiating a monotherapy expansion for IDE892 …

IDEAYA Biosciences (NASDAQ:IDYA) Given New $59.00 Price Target at Truist Financial

IDEAYA Biosciences 2Q 2026: Revenue $8.86M, EPS $(1.22) — 10-Q Summary

IDEAYA Biosciences reported its second-quarter 2026 results, showing collaboration revenue of $8.86 million and a net loss of $(112.45) million, or $(1.22) diluted EPS, due to increased R&D and commercial preparation. The company highlighted positive Phase 2/3 clinical trial results for darovasertib, with an …

IDEAYA BIOSCIENCES, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $31 FROM $37

Leerink Partners has decreased its target price for IDEAYA Biosciences, Inc. (IDYA.O) from $37 to $31. This adjustment was reported by Reuters on August 5, 2026, at 12:21 PM. The article provides this key financial action without further elaborating on the reasons behind the …

IDEAYA Biosciences (IDYA) Stock Faces Loss Pressure Despite Revenue Traction

IDEAYA Biosciences (IDYA) stock saw a modest increase after its Q2 2026 earnings report, which highlighted significant revenue growth but also widening net losses. While the company achieved substantial revenue traction and secured new funding, its increasing cash burn and lack of a clear …

IDEAYA Biosciences (NASDAQ: IDYA) reports $1.24B cash and rising R&D spend

IDEAYA Biosciences reported Q2 2026 collaboration revenue of $8.9 million and a net loss of $112.5 million, with R&D expenses significantly increasing to $108.7 million for the quarter. The company strengthened its liquidity through a June 2026 follow-on offering and at-the-market sales, boosting cash, …

Uveal melanoma trial reports 6.9 months progression-free vs. 3.1

IDEAYA Biosciences (IDYA) announced positive results from its registrational Phase 2/3 OptimUM-02 trial for darovasertib plus crizotinib in metastatic uveal melanoma, meeting its primary endpoint with a median progression-free survival (PFS) of 6.9 months compared to 3.1 months for the investigator's choice arm. The …

IDEAYA Biosciences (NASDAQ:IDYA) Releases Quarterly Earnings Results, Misses Estimates By $0.16 EPS

IDEAYA Posts Q2 Loss as Cash Reaches $1.24 Billion

IDEAYA Biosciences (IDYA) reported a Q2 2026 net loss of $112.5 million ($1.22 per share) on collaboration revenue of $8.9 million, up from the prior quarter. The company announced its cash, cash equivalents, and marketable securities reached $1.24 billion, with cash runway guidance into …

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

IDEAYA Biosciences announced its second-quarter 2026 financial results and provided a business update. The company's registrational OptimUM-02 trial for darovasertib combination in metastatic uveal melanoma met its primary endpoint, with an NDA filing underway. IDEAYA also reported a strong financial position with approximately $1.24 …

IDEAYA Biosciences reports Q2 2026 net loss $112.5M; cash $1.24B after $323M offering

IDEAYA Biosciences reported a net loss of $112.5 million for Q2 2026, ending the period with $1.24 billion in cash, cash equivalents, and marketable securities after a $323 million public offering. The company's OptimUM-02 trial met its primary endpoint, leading to an NDA filing …

IDEAYA Biosciences Q2 Loss Widens From Q1, Revenue Rises

IDEAYA Biosciences (IDYA) reported a wider loss of $1.22 per diluted share in Q2, compared to the previous quarter. Despite the increased loss, the company experienced a rise in revenue during the same period. This article provides a brief overview of IDEAYA's Q2 financial …

Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q2 Revenue $8.9M, vs. FactSet Est of $8.0M

IDEAYA Biosciences, Inc. (IDYA) announced its Q2 revenue of $8.9 million, surpassing FactSet's estimate of $8.0 million. This news comes alongside other recent updates for the company, including Wedbush adjusting its price target to $60 and maintaining an Outperform rating, and the company's Q2 …

Dimensional Fund Advisors LP Increases Position in IDEAYA Biosciences, Inc. $IDYA

Dimensional Fund Advisors LP significantly increased its stake in IDEAYA Biosciences, Inc. (IDYA) by 42% in Q1, now holding 1.33 million shares valued at $44.4 million. Other institutional investors like State Street and Janus Henderson also boosted their positions, with institutional ownership reaching 98.29%. …

IDEAYA Biosciences (IDYA) Expected to Post Earnings on Monday

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences announced inducement grants of stock options to three new employees. These grants were approved by the Compensation Committee of the company's Board of Directors and are made under Nasdaq Listing Rule 5635(c)(4) as an inducement material to the employees entering into employment …

IDEAYA Biosciences grants 260,200 inducement stock options at $36.4 per share

IDEAYA Biosciences issued inducement stock options for 260,200 shares to 14 new employees on July 30, 2026. The exercise price for these options is $36.4 per share, matching the stock's Nasdaq closing price on the grant date. These awards have a 10-year term, with …

14 New IDEAYA Hires Granted Stock Options at $36.40

IDEAYA Biosciences (NASDAQ: IDYA) has granted non-qualified stock options for an aggregate of 260,200 shares to fourteen newly hired employees. These grants were made under the 2023 Employment Inducement Incentive Award Plan, with an exercise price of $36.40 per share, equal to the closing …

Janus Henderson Group PLC Boosts Stake in IDEAYA Biosciences, Inc. $IDYA

Will IDEAYA’s (IDYA) IDE892 Combo Strategy in MTAP‑Deleted Cancers Reshape Its Targeted Oncology Narrative?

IDEAYA Biosciences is expanding its Phase 1/2 trial for IDE892, a PRMT5 inhibitor targeting MTAP-deleted solid tumors, into monotherapy expansion. This move positions IDE892 as a combination backbone for various cancer treatments, potentially reshaping IDEAYA's investment narrative by adding a second pillar to its …

Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50

Mizuho Securities has reiterated its Buy rating on IDEAYA Biosciences (IDYA.US), maintaining a target price of $50. This continued endorsement suggests the firm's confidence in the biotechnology company's future performance and valuation. The decision indicates that Mizuho sees strong potential for growth or continued …

IDEAYA Biosciences, Inc. $IDYA Shares Sold by Redmile Group LLC

IDEAYA Biosciences Inc (IDYA) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for IDEAYA Biosciences Inc (IDYA), covering operating, investing, and financing activities. It includes year-over-year percentage changes and absolute financial figures for various cash flow components. The report also features a FAQ section explaining …

IDEAYA Biosciences (IDYA) Advances IDE892 Trial, Is The Upside Already Priced In?

IDEAYA Biosciences (IDYA) has moved its IDE892 trial into Part 2 monotherapy expansion for MTAP-deleted solid tumors, showcasing positive momentum with recent share price gains. While the company's 15.5x price-to-sales ratio is considered overvalued compared to the broader US biotechs industry, it is undervalued …

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

IDEAYA Biosciences has initiated Part 2 monotherapy expansion of its Phase 1/2 clinical trial for IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor. This expansion focuses on MTAP-deleted solid tumors, specifically non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), building on its unique …